- Home
- Publications
- Publication Search
- Publication Details
Title
Deucravacitinib for the Treatment of Psoriatic Disease
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-08-12
DOI
10.1007/s40257-022-00720-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects
- (2022) Anjaneya Chimalakonda et al. Clinical Pharmacology in Drug Development
- Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
- (2022) Diamant Thaçi et al. Dermatology and Therapy
- Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
- (2022) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System
- (2022) Ziwei Dong et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
- (2022) R. B. Warren et al. ANNALS OF THE RHEUMATIC DISEASES
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
- (2022) April W. Armstrong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors
- (2021) Christine E. Jo et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- POS0198 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
- (2021) P. J. Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
- (2021) Anjaneya Chimalakonda et al. Dermatology and Therapy
- New Topical Therapies for Psoriasis
- (2021) Ana Maria Lé et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- TYK2 inhibition: changing the treatment landscape for psoriasis?
- (2021) Abrahim Abduelmula et al. Expert Review of Clinical Immunology
- Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis
- (2021) Ian M. Catlett et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
- (2020) Miguel Nogueira et al. DRUGS
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
- (2020) April W. Armstrong et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life
- (2020) Sascha Gerdes et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
- (2020) Philip Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
- (2020) Robert Harrington et al. Journal of Inflammation Research
- Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)
- (2019) Xingrui He et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study
- (2019) Kenneth B. Gordon et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
- (2019) Stephen T. Wrobleski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
- (2018) Jason E. Hawkes et al. JOURNAL OF IMMUNOLOGY
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Psoriasis pathogenesis and the development of novel targeted immune therapies
- (2017) Jason E. Hawkes et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Herpes zoster in psoriasis patients treated with tofacitinib
- (2017) Kevin L. Winthrop et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Richard B Warren et al. LANCET
- Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
- (2016) C. A. Dendrou et al. Science Translational Medicine
- Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection
- (2016) Davide Eletto et al. Nature Communications
- Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
- (2015) K L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Small Molecules in the Treatment of Psoriasis
- (2015) Tiago Torres et al. DRUG DEVELOPMENT RESEARCH
- Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study
- (2015) G. Palareti et al. International Journal of Laboratory Hematology
- Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain
- (2015) John S. Tokarski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
- (2015) Alexandra Y. Kreins et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis
- (2015) Wolf-Henning Boehncke et al. LANCET
- Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans
- (2013) Sung O. Park et al. PLoS One
- Genetics of Psoriasis: Evidence for Epistatic Interaction between Skin Barrier Abnormalities and Immune Deviation
- (2012) Judith G.M. Bergboer et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome
- (2012) Sara S. Kilic et al. JOURNAL OF PEDIATRICS
- Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study
- (2012) S. Dogra et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011
- (2012) April W. Armstrong et al. PLoS One
- A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
- (2010) Amy Strange et al. NATURE GENETICS
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- JAK3: A two-faced player in hematological disorders
- (2009) Melanie G. Cornejo et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference
- (2009) David M. Rosmarin et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started